Alpha 2.0
Login Register
» Articles » PMID: 30587548

Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2018 Dec 28
PMID 30587548
Citations 16
Authors
Douglas B Johnson
Justin M Balko
Affiliations
Soon will be listed here.
Abstract

Immune checkpoint inhibitors induce durable responses in some patients with advanced cancer but may simultaneously trigger autoinflammatory immune-related adverse events (irAE). The pathogenesis of irAEs may relate to genetic predisposition, environmental insults, or tumor-host interactions. Elevated expression of certain cytokines may signal subclinical inflammation that evolves into severe irAEs with treatment..

Citing Articles

Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.

Alnemri A, Tekumalla S, Moroco A, Vathiotis I, Tuluc M, Gargano S Cancer Med. 2024; 13(11):e7370.

PMID: 38847087 PMC: 11157197. DOI: 10.1002/cam4.7370.

Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.

Goodman R, Jung S, Balko J, Johnson D Immunol Rev. 2023; 318(1):157-166.

PMID: 37470280 PMC: 10528475. DOI: 10.1111/imr.13249.

A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab.

Gao R, Yang F, Yang C, Zhang Z, Liu M, Xiang C Front Immunol. 2023; 14:1114994.

PMID: 37426639 PMC: 10323425. DOI: 10.3389/fimmu.2023.1114994.

First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function.

Myers J, Parks A, Mahnken J, Young K, Pathak H, Puri R Cancers (Basel). 2023; 15(5).

PMID: 36900405 PMC: 10000599. DOI: 10.3390/cancers15051615.

Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.

Gao L, Li X, Guo Z, Tang L, Peng J, Liu B Medicine (Baltimore). 2023; 101(49):e32240.

PMID: 36626474 PMC: 9750698. DOI: 10.1097/MD.0000000000032240.

References
1.
Patil P, Burotto M, Velcheti V . Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. Expert Rev Mol Diagn. 2018; 18(3):297-305. DOI: 10.1080/14737159.2018.1440209. View
2.
Wang D, Salem J, Cohen J, Chandra S, Menzer C, Ye F . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(12):1721-1728. PMC: 6440712. DOI: 10.1001/jamaoncol.2018.3923. View
3.
Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View
4.
Lim S, Lee J, Gide T, Menzies A, Guminski A, Carlino M . Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy. Clin Cancer Res. 2018; 25(5):1557-1563. DOI: 10.1158/1078-0432.CCR-18-2795. View
5.
Johnson D, Chandra S, Sosman J . Immune Checkpoint Inhibitor Toxicity in 2018. JAMA. 2018; 320(16):1702-1703. DOI: 10.1001/jama.2018.13995. View